C-Abl Inhibitor Imatinib Enhances Insulin Production by β Cells: C-Abl Negatively Regulates Insulin Production via Interfering with the Expression of NKx2.2 and GLUT-2

Chronic myelogenous leukemia patients treated with tyrosine kinase inhibitor, Imatinib, were shown to have increased serum levels of C-peptide. Imatinib specifically inhibits the tyrosine kinase, c-Abl. However, the mechanism of how Imatinib treatment can lead to increased insulin level is unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Chang-Qing, Zhang, Pengcheng, Li, Shiwu, Yuan, Lihui, Xia, Tina, Xie, Chao, Clare-Salzler, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023982/
https://www.ncbi.nlm.nih.gov/pubmed/24835010
http://dx.doi.org/10.1371/journal.pone.0097694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023982/
https://www.ncbi.nlm.nih.gov/pubmed/24835010
http://dx.doi.org/10.1371/journal.pone.0097694

Ejemplares similares